Upgrade to SI Premium - Free Trial

Incyte (INCY) Reiterated at Buy by Stifel on Constructive View for Povorcitinib

March 30, 2026 7:42 AM
Stifel analyst Stephen Willey reiterated a Buy rating and $120.00 price target on Incyte (NASDAQ: INCY).The analyst commented, "We remain ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments